Details of the Drug-Related molecule(s) Interaction Atlas

ML272 Drug Info

N-(2-(4-(2-Oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)-2-naphthamide; CHEMBL492797; 1130067-18-3; ML272; VU0155056-2; SCHEMBL2724877; BDBM87245; cid_53481919; CHEBI:131157; NCGC00386898-01; VU0155056-3; VU0155056-1; US9453017, 3; VU0156056 (1); N-[2-[4-(2-keto-3H-benzimidazol-1-yl)piperidino]ethyl]-2-naphthamide;hydrochloride; N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-naphthalenecarboxamide;hydrochloride; N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]ethyl]naphthalene-2-carboxamide

Cross-matching ID

PubChem CID

25105704

ChEBI ID

CHEBI:131157

TTD Drug ID

DMNEY58

General Information of Drug (ID: DMNEY58)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Phospholipase D1 (PLD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9127005, P2C	DMMT98V	N. A.	N. A.	Patented	[2]
US9453017, 1	DMVQ3IX	N. A.	N. A.	Patented	[1]
US9127005, P2B	DM3R7BT	N. A.	N. A.	Patented	[2]
US9127005, P0L	DMKLYCV	N. A.	N. A.	Patented	[2]
US9453017, 2	DMPH05Y	N. A.	N. A.	Patented	[1]
1-(pyridin-2-yl)piperazine	DMKE7FG	Discovery agent	N.A.	Investigative	[3]
HALOPEMIDE	DMF6V8W	Discovery agent	N.A.	Investigative	[4]
1-(pyridin-4-yl)piperazine	DM78AJ1	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Antiviral therapies with phospholipase D inhibitors. US9453017.
2	Isoform selective phospholipase D inhibitors. US9127005.
3	Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5]decan-4-one privil... Bioorg Med Chem Lett. 2009 Apr 15;19(8):2240-3.
4	Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17.